retatrutide phase 3 trial BREAKING NEWS: Results – A New Chapter in Obesity Medicine?, Retatrutide is rapidly becoming one of the most talked-about investigational therapies in obesity medicine, and the Retatrutide Delivers 22.6% Weight Loss

It is an investigational drug in Phase 3 clinical trials

I have energy to keep up and the confidence to be in every photo

Tyna helps others improve their resilience and metabolic health through her multiple online offerings, social media, and podcast

In September 2023, the FDA added BPC-157 to its Category 2 list of bulk drug substances under its Interim Policy on Compounding, meaning 503A compounding pharmacies and 503B outsourcing facilities are barred from using it in compounded preparations

Bousquet et al., 2020

not site-specific Cycle length: 24 weeks Although BPC-157 doesnt increase hypertrophy directly, its role in reducing inflammation and speeding soft tissue repair makes it a staple in performance-based recovery stacks